– Kriya is developing KRIYA-825 as a potential one-time gene therapy expressing a fusion protein inhibiting the activity of complement C3 and C5 for the treatment of Geographic Atrophy – PALO ...

– Preclinical data support clinical development of KRIYA-825; Phase 1/2 clinical trial in Geographic Atrophy currently underway – – Kriya is developing KRIYA-825 as a potential one-time gene ...

RESEARCH TRIANGLE PARK - Warden Bio, a startup with ties to Duke University, has been bought by Kriya, a gene therapy company with operations in RTP and in Silicon Valley that raised $100 million ...

Kriya Therapeutics, Inc., a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, today announced the clos ...

Kriya Therapeutics has reeled in a whopping $270 million from its series C round, surpassing the $180 million raised in total over the last two years.

Kriya Therapeutics, a fully-integrated gene therapy developer, said today it has completed a $270 million Series C financing that is intended to support the advancement of its pipeline and ...

Matihani-Sambho Bridge In Begusarai To Reduce Travel Time Between North-South Bihar By 70 KM The distance among Begusarai, Munger, Lakhisarai, Bhagalpur and Patna will be less than 40-50 km from ...

Kriya announced an exclusive agreement to license next generation complement-targeted gene therapies for geographic atrophy and other ocular diseases.

Kriya Therapeutics has snapped up Tramontane Therapeutics and will be developing a NASH program sourced from the gene therapy biotech.